Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,641 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Discovery, synthesis, and structure-activity relations of 3,4-dihydro-1H-spiro(naphthalene-2,2'-piperidin)-1-ones as potassium-competitive acid blockers.
Imaeda T, Ono K, Nakai K, Hori Y, Matsukawa J, Takagi T, Fujioka Y, Tarui N, Kondo M, Imanishi A, Inatomi N, Kajino M, Itoh F, Nishida H. Imaeda T, et al. Among authors: nakai k. Bioorg Med Chem. 2017 Jul 15;25(14):3719-3735. doi: 10.1016/j.bmc.2017.05.012. Epub 2017 May 6. Bioorg Med Chem. 2017. PMID: 28522264
Exploration of pyrrole derivatives to find an effective potassium-competitive acid blocker with moderately long-lasting suppression of gastric acid secretion.
Nishida H, Fujimori I, Arikawa Y, Hirase K, Ono K, Nakai K, Inatomi N, Hori Y, Matsukawa J, Fujioka Y, Imanishi A, Fukui H, Itoh F. Nishida H, et al. Among authors: nakai k. Bioorg Med Chem. 2017 Jul 1;25(13):3447-3460. doi: 10.1016/j.bmc.2017.04.034. Epub 2017 Apr 27. Bioorg Med Chem. 2017. PMID: 28483454
Synthesis and evaluation of novel 1H-pyrrolo[2,3-b]pyridine-5-carboxamide derivatives as potent and orally efficacious immunomodulators targeting JAK3.
Nakajima Y, Inoue T, Nakai K, Mukoyoshi K, Hamaguchi H, Hatanaka K, Sasaki H, Tanaka A, Takahashi F, Kunikawa S, Usuda H, Moritomo A, Higashi Y, Inami M, Shirakami S. Nakajima Y, et al. Among authors: nakai k. Bioorg Med Chem. 2015 Aug 1;23(15):4871-4883. doi: 10.1016/j.bmc.2015.05.034. Epub 2015 May 27. Bioorg Med Chem. 2015. PMID: 26071372
Corrigendum to "Synthesis and evaluation of novel 1H-pyrrolo[2,3-b]pyridine-5-carboxamide derivatives as potent and orally efficacious immunomodulators targeting JAK3" [Bioorg. Med. Chem. 23 (2015) 4871-4883].
Nakajima Y, Inoue T, Nakai K, Mukoyoshi K, Hamaguchi H, Hatanaka K, Sasaki H, Tanaka A, Takahashi F, Kunikawa S, Usuda H, Moritomo A, Higashi Y, Inami M, Shirakami S. Nakajima Y, et al. Among authors: nakai k. Bioorg Med Chem. 2017 May 15;25(10):2813. doi: 10.1016/j.bmc.2017.03.043. Epub 2017 Mar 30. Bioorg Med Chem. 2017. PMID: 28366269 No abstract available.
Corrigendum to "Synthesis and evaluation of novel 1H-pyrrolo[2,3-b]pyridine-5-carboxamide derivatives as potent and orally efficacious immunomodulators targeting JAK3" [Bioorg. Med. Chem. 23 (2015) 4871-4883].
Nakajima Y, Inoue T, Nakai K, Mukoyoshi K, Hamaguchi H, Hatanaka K, Sasaki H, Tanaka A, Takahashi F, Kunikawa S, Usuda H, Moritomo A, Higashi Y, Inami M, Shirakami S. Nakajima Y, et al. Among authors: nakai k. Bioorg Med Chem. 2016 Sep 15;24(18):4517. doi: 10.1016/j.bmc.2016.07.015. Epub 2016 Jul 15. Bioorg Med Chem. 2016. PMID: 27544046 No abstract available.
Synthesis and evaluation of 1H-pyrrolo[2,3-b]pyridine derivatives as novel immunomodulators targeting Janus kinase 3.
Nakajima Y, Tojo T, Morita M, Hatanaka K, Shirakami S, Tanaka A, Sasaki H, Nakai K, Mukoyoshi K, Hamaguchi H, Takahashi F, Moritomo A, Higashi Y, Inoue T. Nakajima Y, et al. Among authors: nakai k. Chem Pharm Bull (Tokyo). 2015;63(5):341-53. doi: 10.1248/cpb.c15-00036. Epub 2015 Mar 14. Chem Pharm Bull (Tokyo). 2015. PMID: 25786493 Free article.
Guselkumab in patients with moderately to severely active ulcerative colitis (QUASAR): phase 3 double-blind, randomised, placebo-controlled induction and maintenance studies.
Rubin DT, Allegretti JR, Panés J, Shipitofsky N, Yarandi SS, Huang KG, Germinaro M, Wilson R, Zhang H, Johanns J, Feagan BG, Hisamatsu T, Lichtenstein GR, Bressler B, Peyrin-Biroulet L, Sands BE, Dignass A; QUASAR Study Group. Rubin DT, et al. Lancet. 2025 Jan 4;405(10472):33-49. doi: 10.1016/S0140-6736(24)01927-5. Epub 2024 Dec 17. Lancet. 2025. PMID: 39706209 Clinical Trial.
1,641 results